APOE ɛ4 Allele Testing and Risk of Alzheimer Disease
- 2 February 2021
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (5), 484-485
- https://doi.org/10.1001/jama.2020.15085
Abstract
A 64-year-old man presented with concern about an abnormal genetic test result for apolipoprotein E (APOE) obtained through his primary care physician. He reported forgetfulness and word-finding difficulties for 3 years but performed all activities of daily living independently and was generally healthy. His father and maternal great aunt developed dementia in their 70s. Physical (including neurologic) examination, basic laboratory studies, and brain magnetic resonance imaging results were normal. The Short Test of Mental Status (STMS) score was 33 (maximal attainable score of 38 indicates best performance). Neuropsychological assessment showed average to above-average performance in all cognitive domains, accounting for age and education. Results of his genetic testing for APOE were reported as follows: “This individual possesses an apolipoprotein E genotype (3 and 4) that indicates, with high specificity, that Alzheimer’s disease is the cause of or a contributor to the observed dementia.” Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.This publication has 11 references indexed in Scilit:
- Diagnosis and Management of Dementia: ReviewJAMA, 2019
- Faculty Opinions recommendation of Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia.Published by H1 Connect ,2019
- Relative risk for Alzheimer disease based on complete family historyNeurology, 2019
- Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or DementiaJAMA, 2019
- Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical diseaseAlzheimer's & Dementia, 2018
- APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohortsPLoS Medicine, 2017
- Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer DiseaseJAMA Neurology, 2014
- Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapyNature Reviews Neurology, 2013
- Predictive value of APOE- 4 allele for progression from MCI to AD-type dementia: a meta-analysisJournal of Neurology, Neurosurgery & Psychiatry, 2011
- Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive ImpairmentArchives of Neurology, 2003